Posted on 3/24/21
Novavax Director Sells $883K of Stock
Novavax (NASDAQ:NVAX) director Michael A. McManus has sold 4K shares at an average price of $220.78 per share, according to a regulatory filing released yesterday.Dated March . . .
Posted on 1/11/21
Novavax Executives Sold $46M Worth Company Shares in 2020
Top executives at the COVID-19 vaccine developer Novavax (NASDAQ:NVAX) have sold approximately $46M worth of company stock since the start of 2020, Reuters reported following a . . .
Posted on 9/17/20
Moderna, Inc.: All Signs Point To An Impending Rally
SummaryModerna’s COVID-19 vaccine candidate, a frontrunner to win the FDA emergency use authorization, is ahead of an interim data readout.After a sharp sell-off over the past . . .
Posted on 8/11/20
ResMed: Premium Multiple Needs A Correction As Outlook Turns Gloomy
SummaryThe pandemic-driven demand has fueled a peak in revenue growth and margins for ResMed.A successful vaccine will halt the upsurge as better patient management softens the . . .
Posted on 8/6/20
Emergent BioSolutions: The Indirect COVID-19 Vaccine Play Looks Undervalued
SummaryThe manufacturing deals for candidates set the stage for Emergent to ride the momentum of COVID-19 vaccine development.Until a winner emerges, its antibody therapy can be . . .
Posted on 7/8/20
BJ's Wholesale Club: Growth Prospects Don’t Support Undervaluation
Driven by the grocery stockpiling ahead of lockdowns, the membership warehouses offering value for bulk purchasers have set the tone for U.S. retailers during the pandemic. . . .
Posted on 12/11/19
Intercept Pharmaceuticals: Blockbuster Therapy Unveils An Upside Catalyst
SummaryIntercept is likely to introduce the first successful NASH therapy early next year.The barriers to entry and lack of competition should consolidate market access.While the higher . . .
Posted on 10/9/19
Axsome Therapeutics: Sizable Sales Upside From A Promising Trial Demands A Premium
SummaryAxsome Therapeutics is scheduled to release the topline data from four clinical trials this year.Positive results could enable two NDA filings in 2020 for MDD and . . .
